EyePoint Pharmaceuticals (EYPT) Tops Q3 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Mizuho Securities Starts EyePoint Pharmaceuticals, Inc. (EYPT) at Buy
November 1, 2023 4:05 PM EDTMizuho Securities analyst Graig Suvannavejh initiates coverage on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) with a Buy rating and a price target of $20.00.
The analyst comments "We initiate on EYPT at Buy/$20 (implies ~200% upside). EYPT is advancing EYP-1901 as a novel treatment for retinal diseases,... More



